Citizens JMP raised the firm’s price target on Halozyme (HALO) to $78 from $73 and keeps an Outperform rating on the shares. Halozyme reported Q4 results above consensus expectations while reiterating guidance for 2025 and its longer-term 2026-2028 outlook, the analyst tells investors in a research note. Citizens JMP says it has confidence in the durability of multiple royalty streams well into the 2030s, with upside from current pipeline programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Buy Rating Affirmed: Halozyme’s Robust Growth and Strategic Positioning Drive Positive Outlook
- Halozyme price target raised to $72 from $70 at H.C. Wainwright
- Halozyme Therapeutics Achieves Record Revenue in 2024
- Positive Outlook and Strategic Growth: Brendan Smith’s Buy Rating on Halozyme
- Halozyme reports Q4 EPS $1.06, consensus $1.16